Crystalline polymorphs of Bruton's tyrosine kinase inhibitors

US11820760B2 · kind B2 · utility

Assignee

• Biogen MA Inc. · US

Inventors

• Fengmei Zheng · Quincy, US
• Anton Peterson · Holliston, US
• Kalyan Vasudevan · Cambridge, US
• Chaomin Li · Boston, US
• Daniel B. Patience · Arlington, US
• Yiqing Lin · Lexington, US

Key dates

• Filing date: Oct 15, 2019
• Grant date: Nov 21, 2023
• Expiry date: Aug 1, 2040

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07B2200/13
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

Provided are crystalline forms of (R)-1-(tert-butyl)-N-(8-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-2-(oxetan-3-yl)-2,3,4,5-tetrahydro-1H-benzo[c]azepin-5-yl)-1H-1,2,3-triazole-4-carboxamide, pharmaceutical compositions, methods of use and methods of making thereof.